Your browser doesn't support javascript.
loading
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Rahman, Mohummad Aminur; Gras Navarro, Andrea; Brekke, Jorunn; Engelsen, Agnete; Bindesbøll, Christian; Sarowar, Shahin; Bahador, Marzieh; Bifulco, Ersilia; Goplen, Dorota; Waha, Andreas; Lie, Stein Atle; Gjertsen, Bjørn Tore; Selheim, Frode; Enger, Per Øyvind; Simonsen, Anne; Chekenya, Martha.
Afiliação
  • Rahman MA; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Gras Navarro A; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Brekke J; Haukeland University Hospital, Department of Oncology, Bergen, Norway.
  • Engelsen A; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Bindesbøll C; University of Oslo, Department of Molecular Medicine, Institute of Basic Medical Sciences and Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Oslo, Norway.
  • Sarowar S; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Bahador M; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Bifulco E; University of Bergen, Department of Clinical Science and Core Facility for Metabolomics, Bergen, Norway.
  • Goplen D; Haukeland University Hospital, Department of Oncology, Bergen, Norway.
  • Waha A; University of Bonn, Department of Neuropathology, Bonn, Germany.
  • Lie SA; University of Bergen, Department of Clinical Dentistry, Bergen, Norway.
  • Gjertsen BT; University of Bergen, Department of Clinical Science, Bergen, Norway.
  • Selheim F; Haukeland University Hospital, Department of Internal Medicine, Hematology Section, Bergen, Norway.
  • Enger PØ; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Simonsen A; University of Bergen, Department of Biomedicine, Bergen, Norway.
  • Chekenya M; University of Oslo, Department of Molecular Medicine, Institute of Basic Medical Sciences and Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Oslo, Norway.
Br J Cancer ; 121(7): 545-555, 2019 10.
Article em En | MEDLINE | ID: mdl-31413318
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / O(6)-Metilguanina-DNA Metiltransferase / Bortezomib / Temozolomida / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / O(6)-Metilguanina-DNA Metiltransferase / Bortezomib / Temozolomida / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Noruega